BriaCell Therapeutics (BCT.TO), up 41% in U.S. pre-market trading, on Thursday confirmed the sustained complete resolution of the lung metastasis, first reported in February, two months after initial treatment.
The latest data at four months also demonstrates stable disease elsewhere, the company said.
The patient, a 78-year-old woman with metastatic breast cancer, had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study. At enrollment last November, she had extensive metastases including bone, lymph node and lung involvement. Following Bria-OTS injections every two weeks for six weeks, and subsequent dosing every three weeks, the lung metastasis completely resolved with stable disease elsewhere. This response is now confirmed and shows the potentially promising activity of the Bria-OTS platform as monotherapy, Briacell said.
"This unprecedented anti-cancer response in the first patient dosed with Bria-OTS is an important milestone for us and provides early validation of BriaCell's personalized immunotherapy approach," said Chief Executive Dr. William Williams.
The company's shares were last seen up US$2.30, to US$7.73, in New York trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.